Cary Twyman

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold et al. · The Lancet · 2012 · 1.2K citations · Full text

Life Sciences, Immunology, Neurology +11

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Gavin Giovannoni, Jeffrey Cohen, Alasdair Coles et al. · Neurology · 2016 · 62 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients

Amy E. Lovett‐Racke, Matthew Gormley, Yue Liu et al. · Journal of Neuroimmunology · 2019 · 48 citations · Full text

Life Sciences, Immunology, Neurology +17

Acidities and homolytic bond dissociation energies (BDEs) of benzyl-type carbon-hydrogen bonds in sterically congested substrates

F. G. Bordwell, Jin Cheng, A. V. Satish et al. · The Journal of Organic Chemistry · 1992 · 38 citations

Natural Sciences, Chemistry, Organic Chemistry +12